- Home
- BGB vs ALT Comparison
BGB vs ALT Comparison
Compare BGB & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BGB | ALT |
|---|---|---|
| Founded | 2012 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 504.9M | 415.3M |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | BGB | ALT |
|---|---|---|
| Price | $11.24 | $3.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $17.67 |
| AVG Volume (30 Days) | 197.8K | ★ 3.2M |
| Earning Date | 01-01-0001 | 03-05-2026 |
| Dividend Yield | ★ 9.75% | N/A |
| EPS Growth | N/A | ★ 25.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 105.00 |
| 52 Week Low | $10.47 | $2.87 |
| 52 Week High | $12.65 | $7.73 |
Technical Indicators
Market Signals| Indicator | BGB | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 45.26 | 38.51 |
| Support Level | $10.98 | $2.91 |
| Resistance Level | $11.93 | $4.25 |
| Average True Range (ATR) | 0.18 | 0.17 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 50.76 | 38.10 |
Price Performance
Historical ComparisonAbout BGB Blackstone Strategic Credit 2027 Term Fund of Beneficial Interest
Blackstone Strategic Credit Fund is a diversified, closed-end management investment company. Its primary investment objective is to seek high current income. The secondary objective of the fund is to seek the preservation of capital. Under normal market conditions, the Fund invests at least 80% of its Managed Assets in senior, secured floating-rate loans. The fund also invest in second-lien loans and high yield bonds and employs financial leverage, which may increase risk to the Fund. The Fund has a limited term and absent shareholder approval to extend the life of the Fund.
About ALT Altimmune Inc.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.